PDL1-eBrg

PDL1-eBrg is an engineered regulatory B cell (eBreg) therapy being developed for the treatment of autoimmune diseases, specifically multiple sclerosis (MS). These cells are primary B cells engineered using CRISPR/Cas9 to constitutively express Programmed Death-Ligand 1 (PD-L1) as a regulatory cargo and a B cell receptor (BCR) specific for myelin oligodendrocyte glycoprotein (MOG) from the endogenous IgH locus. Additionally, the cells are modified with a Blimp1 knockout to prevent differentiation into antibody-secreting plasma cells, allowing them to function as non-differentiating decoy B cells that outcompete endogenous B cells for T cell help. In preclinical models of experimental autoimmune encephalomyelitis (EAE), PDL1-eBregs have demonstrated the ability to suppress MOG-specific CD4 T cell activation and inflammatory cytokine secretion (IFN-γ, TNF-α, IL-17), promoting immune tolerance and potentially facilitating CNS repair.

Other names

PD-L1 engineered regulatory B cellsPD-L-1 engineered regulatory B cellsPD-L 1 engineered regulatory B cellsMOG-specific PDL1-eBregs